Posted Dec. 23, 2013 at 2:23 p.m.

Premium Lock Pozen's 'safer aspirin' delayed pending additional clinical study

Published: 2013-12-23 14:23:55
Updated: 2013-12-23 14:23:55

Chairman, CEO John Plachetka  Chairman, CEO John Plachetka Image 1 of 2 · Next Image…

Pozen will conduct a phase I trial comparing two dosages of its safer aspirin in order to answer FDA questions about its effects. Read more about the additional clinical study....

Read More
Read More

WRAL TechWire any time: Twitter, Facebook

Copyright 2017 WRAL TechWire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL TechWire and WRAL editors. Read more articles…

Please Log In to add a comment.

Latest for Insiders